The stock of Protagonist Therapeutics Inc (PTGX) has gone up by 4.65% for the week, with a 27.22% rise in the past month and a 2.59% rise in the past quarter. The volatility ratio for the week is 1.87%, and the volatility levels for the past 30 days are 1.96% for PTGX. The simple moving average for the past 20 days is 13.74% for PTGX’s stock, with a 28.19% simple moving average for the past 200 days.
Is It Worth Investing in Protagonist Therapeutics Inc (NASDAQ: PTGX) Right Now?
Protagonist Therapeutics Inc (NASDAQ: PTGX) has a price-to-earnings ratio that is above its average at 74.04x. The stock has a 36-month beta value of 2.25. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PTGX is 58.31M, and at present, short sellers hold a 8.93% of that float. On June 13, 2025, the average trading volume of PTGX was 1.10M shares.
PTGX) stock’s latest price update
The stock price of Protagonist Therapeutics Inc (NASDAQ: PTGX) has surged by 1.77 when compared to previous closing price of 55.34, but the company has seen a 4.65% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-06-01 that NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeti.
Analysts’ Opinion of PTGX
Many brokerage firms have already submitted their reports for PTGX stocks, with Goldman repeating the rating for PTGX by listing it as a “Neutral.” The predicted price for PTGX in the upcoming period, according to Goldman is $47 based on the research report published on December 06, 2024 of the previous year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see PTGX reach a price target of $62. The rating they have provided for PTGX stocks is “Outperform” according to the report published on December 06th, 2024.
Wedbush gave a rating of “Outperform” to PTGX, setting the target price at $58 in the report published on November 05th of the previous year.
PTGX Trading at 20.98% from the 50-Day Moving Average
After a stumble in the market that brought PTGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.06% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTGX starting from MOLINA ARTURO MD, who sale 10,000 shares at the price of $57.03 back on Jun 10 ’25. After this action, MOLINA ARTURO MD now owns 83,892 shares of Protagonist Therapeutics Inc, valued at $570,300 using the latest closing price.
MOLINA ARTURO MD, the Chief Medical Officer of Protagonist Therapeutics Inc, sale 10,000 shares at $55.51 during a trade that took place back on Jun 09 ’25, which means that MOLINA ARTURO MD is holding 83,892 shares at $555,100 based on the most recent closing price.
Stock Fundamentals for PTGX
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.99 for the gross margin
The net margin for Protagonist Therapeutics Inc stands at 0.27. The total capital return value is set at 0.04. Equity return is now at value 8.99, with 8.19 for asset returns.
Based on Protagonist Therapeutics Inc (PTGX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 29.66.
Currently, EBITDA for the company is 252.84 million with net debt to EBITDA at -4.48. When we switch over and look at the enterprise to sales, we see a ratio of 16.18. The receivables turnover for the company is 7.67for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.26.
Conclusion
To sum up, Protagonist Therapeutics Inc (PTGX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
